MYM Nutraceuticals Investor Dashboard

Company Overview:

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of Cannabis and hemp.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

[stock_market_chart symbol=”MYM.CN” range=”1y” settings='{“primaryChartType”:”smoothedLine”,”width”:”100%”,”height”:”350px”,”marginTop”:0,”marginBottom”:0,”marginLeft”:10,”marginRight”:10,”primaryPanelTitle”:”Price”,”secondaryPanelTitle”:”Volume”,”fontSize”:13,”color”:”#383838″,”primaryLineColor”:”#000″,”primaryLineColorAlpha”:0.15,”secondaryLineColor”:”#000″,”secondaryLineColorAlpha”:0.15,”backgroundColor”:”#fff”,”gridColor”:”#e0e0e0″,”gridAlpha”:0.8,”cursorColor”:”#ba0000″,”cursorAlpha”:0.8,”scrollbarBackgroundColor”:”#fff”,”scrollbarSelectedBackgroundColor”:”#000″,”scrollbarGraphFillColor”:”#000″,”scrollbarSelectedGraphFillColor”:”#000″,”primaryLineThickness”:0,”secondaryLineThickness”:0,”gridThickness”:0,”precision”:2,”thousandsSeparator”:”,”,”decimalSeparator”:”.”,”usePrefixes”:false,”mouseWheelZoomEnabled”:false,”cursorEnabled”:false,”exportEnabled”:false,”scrollbarEnabled”:false,”legendEnabled”:false,”periods”:”1W,1M,6M,YTD,1Y,ALL”,”defaultPeriod”:”1y”}’]

Key Share Information:

Current Share Price$0.12
Market Capitalization (in Millions)$15.09
Last Quarter (Share Data)2/28/2019
Shares Outstanding (in Millions)125.72
Options (in Millions)9.11
Warrants (in Millions)14.09
Fully Diluted (in Millions)148.91
<th<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td<tr<td
<!DOCTYPEhtml><metaname="google"content="notranslate"><metaname="viewport"content="target-densitydpi=device-dpi,user-scalable=1,minimum-scale=1,maximum-scale=2.5,initial-scale=1,width=device-width"><metahttp-equiv="X-UA-Compatible"content="IE=edge;"><metaname="referrer"content="origin">MYM</td><td class="column-11">Nutraceuticals</td><td class="column-12">-</td><td class="column-13">Google</td><td class="column-14">Drive<linkrel="shortcuticon"href="//ssl.gstatic.com/docs/spreadsheets/favicon3.ico"><linkhref='/static/spreadsheets2/client/css/2968578022-waffle_k_ltr.css'type='text/css'rel='stylesheet'nonce="Fw9E7jRvoxHul7G8hNScZg"><styletype="text/css"nonce="Fw9E7jRvoxHul7G8hNScZg">
html{overflow:visible;}
#sheets-viewport{overflow:auto;}
#sheets-viewport.widget-viewport{overflow:hidden;}
.grid-container{overflow:visible;background:white;}
.grid-table-container{overflow:visible;}
#top-bar{
margin:0;
overflow:hidden;
}
#top-bar{
border-bottom:1pxsolid#ccc;
padding:6px6px0;
}
#doc-title{padding-bottom:5px;}
#doc-title.name{font-size:15px;}
#sheet-menu{
font-size:13px;
margin:6px00;
padding:005px;
}
#sheet-menuli{
display:inline;
list-style-type:none;
margin:0;
padding:5px8px;
}
#sheet-menuli.active{
background-color:#fff;
font-weight:bold;
border:1pxsolid#999;
}
#top-bar#sheet-menuli.active{
border-bottom:0;
}
#sheet-menua,#sheet-menua:visited{color:#07c;}
#footer{
background:#f0f0f0;
border-top:1px#cccsolid;
border-bottom:1px#cccsolid;
font-size:13;
padding:10px10px;
}
.dash{
padding:06px;
}
.ritz.wafflea{color:inherit;}.ritz.waffle.s1{background-color:#ffffff;text-align:center;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}.ritz.waffle.s0{background-color:#ffffff;text-align:left;color:#000000;font-family:'Arial';font-size:10pt;vertical-align:bottom;white-space:nowrap;direction:ltr;padding:2px3px2px3px;}<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">
varactiveSheetId;
functionswitchToSheet(id){
if(document.getElementById('sheet-menu')){
document.getElementById('sheet-button-'+activeSheetId)
.className='';
document.getElementById('sheet-button-'+id).className='active';
}
document.getElementById(activeSheetId).style.display='none';
document.getElementById(id).style.display='';
activeSheetId=id;
//posObjs()isdefinedinembeddedObjectJs(seeEmbeddedObjectHtmlBuilder.java)
posObjs();
returnfalse;
}
functioninit(){
varoptPageSwitcher;
functionresize(){
varoptMobileWebHeader=document.getElementById('docs-ml-header-id');
varoptTopBar=document.getElementById('top-bar');
varoptFooter=document.getElementById('footer');
varsheetsViewport=document.getElementById('sheets-viewport');
if(optMobileWebHeader){
sheetsViewport.style.marginTop=optMobileWebHeader.offsetHeight+
(optTopBar?optTopBar.offsetHeight:0)+'px';
}
varadjustedHeight=window.innerHeight-
(optTopBar?optTopBar.offsetHeight:0)-
(optFooter?optFooter.offsetHeight:0);
varadjustedWidth=window.innerWidth;
sheetsViewport.style.width=(adjustedWidth+'px');
sheetsViewport.style.height=(adjustedHeight+'px');
if(optPageSwitcher){
optPageSwitcher.resize(adjustedWidth,adjustedHeight);
}
}
resize();
window.onresize=resize;
varcurrentUrl=window.location.href;
varnewUrl=currentUrl.replace('?sle=true&','?');
newUrl=newUrl.replace('?sle=true','');
newUrl=newUrl.replace('&sle=true&','&');
newUrl=newUrl.replace('&sle=true','');
window.history.replaceState(null,'',newUrl);
}
<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">_docs_flag_initialData={"docs-mwid":false,"docs-smheo":false,"info_params":{"includes_info_params":true},"ilcm":{"eui":"ADFN-ctoHzWx9j47QMwHvC0oA13I7GJCkxvKJTCVQTTUU5ZYqxEV1bNi0EwGJn7mYxWxdHBMXlSK","je":1,"sstu":1623926851831000,"si":"CNSQlPm-nvECFVaGqwcd6RgGyw","gsc":0,"ei":[5707711,5703186,5731094,5708862,5705301,5714628,5707197,5728103,5737700,5700019,5713152,5723284,5717118,5704063,5711808,5710677,5709709,5737898,5733710,5714961,5715515,5709892,5707385,5708480,5709381,5707047,5715399,5715637,5719170,5706133,5714843,5716141,5738168,5703913,5723871,5712352,5702767,5707943,5702912,5710637,5711708,5711850,5720479,5737401,5720568,5725052,5722301,5712033,5704621,5704883,5700559,5721815,5719212,5707609,5710645,5717949,5713207,5711471,5739056,5701903,5724085,5702135,5708574,5721004,5708886,5733973,5706601,5733570,5737254,5713227,5728335,5732963,5725300,5725338,5720788,5713681,5705777,5714796,5712469,5716149,5700884,5714326,5724916,5709476,5711765,5713195,5728567,5716028,5704144,5720487,5735134,5715364,5707986,5720483,5710746,5706169,5711550,5712929,5720925,5711099,5721764,5704641,5711155,5720595,5728475,5702849,5719535,5713597,5714322,5720516,5717161,5713223,5707204,5705040,5701034,5707856,5711012,5703837,5730285,5713049,5712909,5735509,5714674,5702445,5714967,5734352,5713605,5710476,5711957,5720714,5703591,5727257,5724896,5708974,5706933,5710938,5724533,5703027,5729546,5712905,5711297,5722346,5712525,5710933,5713542,5728515,5707445,5710542,5715641,5702785,5712298,5708870,5719527,5714330,5735281,5728083,5711685,5722409,5715222,5727901,5731530,5719462,5709661,5727063,5721344,13702623,5706069,5710893,5712211,5731412,5712477,5703839,5711826,5717070,5713191,5730290,5727853,5716457,5702936,5705223,5706270,5731783,5711524,5713554,5707819,5703022,5703815,5703182,5719482,5712373,5711769,5725742,5737153,5734571,5705493,5720060,5700422,5721012,5719531,5714839,5726110,5705581,5712913,5709357,5735670,5722370,5719651,5711230,5704581,5728945,5711889,5715246,5725511,5727042,5712635,5707425,5706523,5721361,5719502,5700446,5728807,5722189,5719418,5706661,5734994,5722567,5714445,5710692,5736924,5714550,5713333,5701650,5726190,5703762,5721307,5726595,5714310,5707137,5712473,5715824,5709447,5730867,5705649,5716416,5703259,5738433,5735806,5709085,5713211,5701594,5723679,5729072,5706007,5706751,5729206,5716145,5713657,5707657,5735630,5723365,5727624],"crc":0,"cvi":[]},"drive_url":"//drive.google.com?usp\u003dsheets_web","docs-ehr":true,"docs-sup":"/spreadsheets"};_docs_flag_cek='';if(window['DOCS_timing']){DOCS_timing['ifdld']=newDate().getTime();}<scriptnonce="pV1eZhB8Boz+dAbXLifK1Q">document.addEventListener('DOMContentLoaded',init);<bodyclass="docs-gm"><divid="top-bar"><divid="doc-title"><spanclass="name">MYMNutraceuticals:KeyShareInfo2<divid="sheets-viewport"><divid="1294638516"style="display:none;position:relative;"dir="ltr"><divclass="ritzgrid-container"dir="ltr"><tableclass="waffle"cellspacing="0"cellpadding="0">
class="row-headerfreezebar-origin-ltrheader-shimrow-header-shim"><thid="1294638516C0"style="width:191px;"class="header-shim"><thid="1294638516C1"style="width:100px;"class="header-shim">
style="height:20px"><thid="1294638516R0"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">1<tdclass="s0">EnterpriseValue(inMIllions)class="s1">$14.24
style="height:20px"><thid="1294638516R1"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">2<tdclass="s0">TTMRevenueclass="s1">$1.78
style="height:20px"><thid="1294638516R2"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">3<tdclass="s0">TTMGrowthMargin%class="s1">65.27%
style="height:20px"><thid="1294638516R3"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">4<tdclass="s0">TTMOperatingExpensesclass="s1">$16.26
style="height:20px"><thid="1294638516R4"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">5<tdclass="s0">TTMOCFclass="s1">-$8.63
style="height:20px"><thid="1294638516R5"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">6<tdclass="s0">P/STTMclass="s1">8.47
style="height:20px"><thid="1294638516R6"style="height:20px;"class="row-headers-backgroundrow-header-shim"><divclass="row-header-wrapper"style="line-height:20px">7<tdclass="s0">P/S(LastQuarterRunRate)class="s1">#DIV/0!
<divid="footer">Publishedby<atarget="_blank"title="LearnmoreaboutGoogleSheets"href="https://docs.google.com/spreadsheets/?usp=sheets_web">GoogleSheets<spanclass="dash">–<ahref="https://docs.google.com/abuse?id=AKkXjoxJPPdT2XZQJ9j1xk56iAncfZHswcfOdDDCv4pDyGeDPRtPlG4JrPFvJQk1Nj2IigePBFtgXVU3uPjrW-o:0">ReportAbuse<spanclass="dash">–Updatedautomaticallyevery5minutes
<scripttype="text/javascript"nonce="pV1eZhB8Boz+dAbXLifK1Q">activeSheetId='1294638516';switchToSheet('1294638516');

Key Balance Sheet Information (in Millions $CAD):

 CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Cash$0.11$0.32$0.55$0.27$2.04$10.11$6.63$1.74$0.91$1.72
Biological Assets
Inventory$0.04$0.03$0.06$0.10$1.06$1.11$0.81$0.77
Total Assets$0.13$0.49$1.77$2.12$6.62$20.45$21.11$22.50$20.27$20.04
Net Tangible Assets$0.12$0.48$0.87$1.05$4.99$16.89$17.22$18.61$17.17$16.94
Intangibles/Goodwill$0.00$0.00$0.90$1.07$1.63$3.56$3.89$3.89$3.10$3.10
Total Liabilities$0.42$0.35$0.26$0.25$0.57$1.28$1.20$2.95$1.16$0.87

Key Operating Items (Quarterly in Millions $CAD):

 CYQ4'16CYQ1'17CYQ2'17CYQ3'17CYQ4'17CYQ1'18CYQ2'18CYQ3'18CYQ4'18CYQ1'19
Revenue$0.14$0.28$0.40$0.48$1.78
Change in Fair Value of Biologial Assets
Gross Margin$0.06$0.19$0.25$0.40$1.16
Marketing and Sales
Investor Relations$0.00$0.01$0.02$0.12$0.32$0.58$1.570.230.34$0.43
Total Operating Expenses$0.04$0.10$0.88$0.79$1.25$2.20$6.782.732.78$3.98
Operating Cash Flow (Quarterly)-$0.03-$0.21-$0.43-$1.09-$1.60-$3.75-4.08-$0.80
Investing Cash Flow (Quarterly)-$0.07$0.02-$1.70-$2.70-$1.88-1.61-$0.03
Financing Cash Flow (Quarterly)$0.00$0.48$0.64$4.56$12.36$2.154.87$1.64

Listing Statement

Share
Tweet
Share